{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:22Z","timestamp":1793121502268,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.breast.2026.104889","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:24:27Z","timestamp":1785194667000},"page":"104889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA"],"prefix":"10.1016","volume":"89","author":[{"given":"Shixian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-0224","authenticated-orcid":false,"given":"Lei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8144-6220","authenticated-orcid":false,"given":"Shunping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104889_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2026.104889_bib2","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104889_bib3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104889_bib4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104889_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-023-03238-2","article-title":"A network meta-analysis of efficacy and safety for first-line and second\/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer","volume":"22","author":"Shao","year":"2024","journal-title":"BMC Med"},{"key":"10.1016\/j.breast.2026.104889_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103815","volume":"78","author":"Keskinkilic","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104889_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jsbmb.2017.07.001","article-title":"Treatment for the endocrine resistant breast cancer: current options and future perspectives","volume":"172","author":"Liu","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.breast.2026.104889_bib8","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.24.00110","article-title":"Phase I\/Ib trial of inavolisib plus palbociclib and endocrine therapy for PIK3CA-Mutated, hormone receptor-positive, human epidermal growth factor receptor 2-Negative advanced or metastatic breast cancer","volume":"42","author":"Jhaveri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104889_bib9","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-Mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104889_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104889_bib11","article-title":"Breast cancer, version 4.2026, NCCN clinical practice guidelines in oncology","volume":"24","author":"Gradishar","year":"2026","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104889_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jval.2022.06.011","article-title":"Distributional cost-effectiveness analysis of health technologies: data requirements and challenges","volume":"26","author":"Meunier","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104889_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104889_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40273-019-00845-x","article-title":"Evaluating partitioned survival and markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes","volume":"38","author":"Smare","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2026.104889_bib15","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104889_bib16","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1136\/heartjnl-2017-311816","article-title":"The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit","volume":"103","author":"Messori","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.breast.2026.104889_bib17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"Ishak","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2026.104889_bib18","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials--extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.breast.2026.104889_bib19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.breast.2026.104889_bib20","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djad135","article-title":"Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective","volume":"115","author":"Yoo","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104889_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Lang","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104889_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40273-023-01245-y","article-title":"Cost effectiveness of CDK4\/6 inhibitors in the first-line treatment of HR+\/HER2- metastatic breast cancer in postmenopausal women in the USA","volume":"41","author":"Masurkar","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2026.104889_bib23","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/annonc\/mdx201","article-title":"Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer","volume":"28","author":"Mamiya","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104889_bib24","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.clbc.2021.06.001","article-title":"Evaluation of tucatinib in HER2-Positive breast cancer patients with brain metastases: a United States-based cost-effectiveness analysis","volume":"22","author":"Dong","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2026.104889_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104889_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.breast.2026.104889_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1634\/theoncologist.12-4-478","article-title":"Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients","volume":"12","author":"Bennett","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104889_bib28","first-page":"219","article-title":"The economic burden of supportive care of cancer patients","volume":"12","author":"Elting","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2026.104889_bib29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.clinthera.2019.04.033","article-title":"Cost-effectiveness analysis of adding palbociclib as a second-line endocrine therapy for HR(+)\/HER2(-) metastatic breast cancer from the US and Chinese perspectives","volume":"41","author":"Zhang","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.breast.2026.104889_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2026.104693","article-title":"Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR(+)\/HER2(-)advanced breast cancer","volume":"85","author":"Zhu","year":"2026","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104889_bib31","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MLR.0000000000001417","article-title":"Assessing the impact of EQ-5D country-specific value sets on cost-utility outcomes","volume":"59","author":"van Dongen","year":"2021","journal-title":"Med Care"},{"key":"10.1016\/j.breast.2026.104889_bib32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1186\/s12885-022-10325-9","volume":"22","author":"Mahtani","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.breast.2026.104889_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2026.104889_bib34","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10198-012-0419-2","article-title":"Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia","volume":"14","author":"Tolley","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.breast.2026.104889_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.clinthera.2023.07.014","article-title":"Cost-effectiveness of trastuzumab deruxtecan for HER2-low advanced breast cancer in the United States","volume":"45","author":"Peng","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.breast.2026.104889_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/11584630-000000000-00000","article-title":"Sensitivity analysis in cost-effectiveness studies: from guidelines to practice","volume":"29","author":"Jain","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2026.104889_bib37","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0272989X8500500205","article-title":"Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach","volume":"5","author":"Doubilet","year":"1985","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.breast.2026.104889_bib38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","article-title":"Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working Group-6","volume":"32","author":"Briggs","year":"2012","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.breast.2026.104889_bib39","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2217\/fon-2022-1228","article-title":"Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA","volume":"20","author":"Ndirangu","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.breast.2026.104889_bib40","doi-asserted-by":"crossref","DOI":"10.1177\/15330338261444965","article-title":"Economic evaluation of inavolisib combined with palbociclib-fulvestrant for PIK3CA-Mutated, HR+\/HER2- advanced breast cancer in USA","volume":"25","author":"Zeng","year":"2026","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104889_bib41","first-page":"1385","article-title":"Inavolisib-based therapy for PIK3CA-Mutated advanced Male breast cancer: a cost-effectiveness analysis","volume":"17","author":"Huang","year":"2025","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2026.104889_bib42","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40261-023-01325-z","article-title":"Is alpelisib plus fulvestrant cost-effective for treating PIK3CA-Mutation, HR+\/HER2- advanced breast cancer in the USA?","volume":"43","author":"Wu","year":"2023","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.breast.2026.104889_bib43","year":"2022"},{"key":"10.1016\/j.breast.2026.104889_bib44","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:26:48Z","timestamp":1789612008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":44,"alternative-id":["S0960977626001992"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104889","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of inavolisib-based therapy in PIK3CA-mutated advanced breast cancer in the USA","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104889"}}